Literature DB >> 12175898

Tetrandrine cytotoxicity and its dual effect on oxidative stress-induced apoptosis through modulating cellular redox states in Neuro 2a mouse neuroblastoma cells.

Quanri Jin1, Chulhun Kang, Yunjo Soh, Nak Won Sohn, Juhie Lee, Yong Ho Cho, Hyung Hwan Baik, Insug Kang.   

Abstract

Tetrandrine (TET), a plant alkaloid, is known primarily as a non-selective Ca(2+) channel blocker. On the contrary to the cytoprotective effect on ischemia/reperfusion injury, TET has also been reported to cause cytotoxicity. In this study, we wished to understand the apparently disparate effects of this potential drug and thus investigated molecular mechanisms on proliferation and apoptosis and its effect on oxidative stress-induced apoptosis in Neuro 2a mouse neuroblastoma cells. We showed that TET, at high concentrations, induced cell cycle arrest and apoptosis through oxidative stress with following observations. Firstly, 10 microM TET elevated the reactive oxygen species (ROS) level and accordingly depleted glutathione (GSH) content. Secondly, pretreatment with antioxidants (NAC or GSH) protected cells from TET-induced apoptosis. We also demonstrated that treatment with 10 microM TET caused not only induction of p53, p21(waf1), and Bax, but also nuclear translocation of p53 and hypo-phosphorylation of pRb concurrently. Our important finding is that the concentration-dependent dual effect of TET, either inhibiting or promoting cell death induced by H(2)O(2) was observed, probably through regulating redox balance, which was well reflected on the GSH content in each condition. Besides, inhibition of Ca(2+) influx protected cells from H(2)O(2)-induced apoptosis even in the presence of 10 microM TET. Taken together, our data suggest that TET regulation of cellular redox states may play a major role in its dual action of cytotoxicity and cytoprotection.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12175898     DOI: 10.1016/s0024-3205(02)01989-6

Source DB:  PubMed          Journal:  Life Sci        ISSN: 0024-3205            Impact factor:   5.037


  7 in total

1.  Tetrandrine and thapsigargin release arachidonic acid from cells in culture and stimulate prostacyclin production in rat liver cells, but may do so by different pathways.

Authors:  Lawrence Levine
Journal:  BMC Pharmacol       Date:  2005-06-24

2.  Tetrandrine protects mouse retinal ganglion cells from ischemic injury.

Authors:  Weiyi Li; Chen Yang; Jing Lu; Ping Huang; Colin J Barnstable; Chun Zhang; Samuel S Zhang
Journal:  Drug Des Devel Ther       Date:  2014-03-21       Impact factor: 4.162

Review 3.  The potential of tetrandrine as a protective agent for ischemic stroke.

Authors:  Yun Chen; Ya-Hui Tsai; Sheng-Hong Tseng
Journal:  Molecules       Date:  2011-09-16       Impact factor: 4.411

Review 4.  Progress on structural modification of Tetrandrine with wide range of pharmacological activities.

Authors:  Liuying Mo; Fan Zhang; Feng Chen; Lei Xia; Yi Huang; Yuemi Mo; Lingqiu Zhang; Daquan Huang; Shunli He; Jiagang Deng; Erwei Hao; Zhengcai Du
Journal:  Front Pharmacol       Date:  2022-08-16       Impact factor: 5.988

Review 5.  Targeting the two-pore channel 2 in cancer progression and metastasis.

Authors:  Kathryn A Skelding; Daniel L Barry; Danielle Z Theron; Lisa F Lincz
Journal:  Explor Target Antitumor Ther       Date:  2022-02-28

6.  Otoprotective Effects of Stephania tetrandra S. Moore Herb Isolate against Acoustic Trauma.

Authors:  Yan Yu; Bing Hu; Jianxin Bao; Jessica Mulvany; Eric Bielefeld; Ryan T Harrison; Sarah A Neton; Partha Thirumala; Yingying Chen; Debin Lei; Ziyu Qiu; Qingyin Zheng; Jihao Ren; Maria Cristina Perez-Flores; Ebenezer N Yamoah; Pezhman Salehi
Journal:  J Assoc Res Otolaryngol       Date:  2018-09-05

7.  Tetrandrine combined with gemcitabine and Cisplatin for patients with advanced non-small cell lung cancer improve efficacy.

Authors:  Wenchao Liu; Ju Zhang; Cheng Ying; Qianrong Wang; Chen Yan; Yang Jingyue; Yu Zhaocai; Xue Yan; Shi Heng-Jun; Jiang Lin
Journal:  Int J Biomed Sci       Date:  2012-03
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.